Anti-tumor-promoting activities of the roots of Panax notoginseng (1)

Natural Medicines

Volumn 50, Issue 2, 1996, Pages 158-162

  Konoshima, Takao ^a   Takasaki, Midori ^a   Tokuda, Harukuni ^b  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

anti tumor promoter; cancer chemoprevention; ginsenoside Rg1; Panaz notoginseng; two stage carcinogenesis

Indexed keywords

4 NITROQUINOLINE 1 OXIDE; 7,12 DIMETHYLBENZ[A]ANTHRACENE; DIETHYLNITROSAMINE; GINSENOSIDE; GINSENOSIDE RG 1; GLYCEROL; PHENOBARBITAL; PHORBOL 13 ACETATE 12 MYRISTATE;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DRUG DETERMINATION; DRUG ISOLATION; EPSTEIN BARR VIRUS; FEMALE; GINSENG; LIVER TUMOR; LUNG TUMOR; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PLANT ROOT; SKIN PAPILLOMA; VIRUS INHIBITION;

EID: 0029992141     PISSN: 13403443     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. A part of this work was presented at the 10th Symposium on the Development and Application of Naturally Occurring Drug Materials, August 1995, Abstracts of Papers, p. 45.
2. I. Berenblum, Cancer Res., 1, 807 (1941).
3. N. Yamamoto, K. Bister, H. Zur Hausen, Nature (Lond.), 276, 553 (1979) ; A. K. Verma, T. J. Slaga, P. W. Wertz, G. C. Mueller, R. K. Boutwell, Cancer Res., 40, 2367 (1980); T. Kakizoe, K. Takai, K. Tobisu, M. Ohtani, S. Sato, Jpn. J. Cancer Res., 79, 235 (1988).
4. N. Yamamoto, K. Bister, H. Zur Hausen, Nature (Lond.), 276, 553 (1979) ; A. K. Verma, T. J. Slaga, P. W. Wertz, G. C. Mueller, R. K. Boutwell, Cancer Res., 40, 2367 (1980); T. Kakizoe, K. Takai, K. Tobisu, M. Ohtani, S. Sato, Jpn. J. Cancer Res., 79, 235 (1988).
5. N. Yamamoto, K. Bister, H. Zur Hausen, Nature (Lond.), 276, 553 (1979) ; A. K. Verma, T. J. Slaga, P. W. Wertz, G. C. Mueller, R. K. Boutwell, Cancer Res., 40, 2367 (1980); T. Kakizoe, K. Takai, K. Tobisu, M. Ohtani, S. Sato, Jpn. J. Cancer Res., 79, 235 (1988).
6. T. Konoshima, M. Takasaki, T. Tatsumoto, M. Kozuka, R. Kasai, O. Tanaka, R.-L. Nie, H. Tokuda, H. Nishino, A. Iwashima, Biol. Pharm. Bull., 17, 668 (1994) and references cited therein.
7. T. Konoshima, M. Takasaki, M. Kozuka, A. Inada, T. Nakanishi, H. Tokuda, T. Matsumoto, Shoyakugaku Zasshi, 43, 135 (1989).
8. M. Takasaki, T. Konoshima, M. Kozuka, H. Tokuda, Biol. Pharm. Bull., 18, 435 (1995).
9. T. Konoshima, H. Tokuda, M. Kozuka, E. Okamoto, M. Tanabe, Shoyakugaku Zasshi, 41, 344 (1987).
10. T. Konoshima, M. Takasaki, M. Kozuka, H. Tokuda, Yakugaku Zasshi, 114, 248 (1994) and references cited therein.
11. H. Tokuda, T. Konoshima, M. Kozuka, T. Kimura, Oncology, 48, 77 (1991); K. Ujita, Y. Takaishi, H. Tokuda, H. Nishino, A. Iwashima, T. Fujita, Cancer Lett., 1993, 129.
12. H. Tokuda, T. Konoshima, M. Kozuka, T. Kimura, Oncology, 48, 77 (1991); K. Ujita, Y. Takaishi, H. Tokuda, H. Nishino, A. Iwashima, T. Fujita, Cancer Lett., 1993, 129.
13. Jiangsu New Medical College, ed., "Chinese Materia Medica," Shanghai People's Pub. House, Shanghai, 1977, p. 54.
14. G. Henle, W. Henle, J. Bacteriol., 91, 1248 (1966).
15. C. E. Weeks, T. J. Slaga, H. Hennings, G. L. Gleason, W. M. Bracken, J. Natl. Cancer Inst., 63, 401 (1979); H. Tokuda, H. Ohigashi, K. Koshimizu, Y. Ito, Cancer Lett., 1986, 279.
16. C. E. Weeks, T. J. Slaga, H. Hennings, G. L. Gleason, W. M. Bracken, J. Natl. Cancer Inst., 63, 401 (1979); H. Tokuda, H. Ohigashi, K. Koshimizu, Y. Ito, Cancer Lett., 1986, 279.
17. Y. Inayama, Jpn. J. Cancer Res. (Gann), 77, 345 (1986).
18. G. D. Porta, T. A. Dragani, G. Mnenti, Toxicol. Pathol., 15, 229 (1987).
19. T. Konoshima, M. Takasaki, M. Kozuka, T. Nagao, H. Okabe, N. Irino, T. Nakasumi, H. Tokuda, H. Nishino, Biol. Pharm. Bull., 18, 284 (1995).
20. H. Yamaguchi, R. Kasai, H. Matsuura, O. Tanaka, T. Fuwa, Chem. Pharm. Bull., 36, 3468 (1988).
21. As inhibitory principles of EBV-EA activation, other compounds will be isolated from active extract of P. notoginseng. The isolation of other active constituents are in progress.